Cancer medicine · 2025
Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caracciolo Daniele, D'Aquino Giuseppe, Froio Caterina, Romeo Caterina, Bosco Vincenzo, Pensabene Giulia, Tedesco Ludovica, Tagliaferri Pierosandro, Tassone Pierfrancesco
Аннотация
BACKGROUND: The COVID-19 pandemic significantly increased mortality risks for individuals with hematological malignancies.
PATIENTS AND METHODS: We conducted a single-center observational study, focusing on the late pandemic phase of the infection (2022-2023), to identify risk factors associated with COVID-19 outcomes in vaccinated patients with hematological malignancies.
RESULTS: Eighty-five COVID-19 cases were recorded among patients with hematological malignancies, primarily Multiple Myeloma (MM) (38.8%), chronic lymphocytic leukemia (CLL) (10.6%) and Non-Hodgkin Lymphoma (NHL) (35.3%). Despite a high COVID-19 vaccination rate (97.6%), severe/critical illness occurred in 23.5% of patients. The overall COVID-19-related mortality rate was 22.4%, with a 30-day mortality rate of 11.8%. Although mortality rates significantly decreased over the observation time (27.7% vs. 16.7%), this trend was not confirmed in critical infection carriers.
CONCLUSION: Our data confirm that, despite a reduction in critical infections and overall mortality rates over time, patients with hematological malignancies remain at high risk during the endemic phase of SARS-CoV-2 infection.
PATIENTS AND METHODS: We conducted a single-center observational study, focusing on the late pandemic phase of the infection (2022-2023), to identify risk factors associated with COVID-19 outcomes in vaccinated patients with hematological malignancies.
RESULTS: Eighty-five COVID-19 cases were recorded among patients with hematological malignancies, primarily Multiple Myeloma (MM) (38.8%), chronic lymphocytic leukemia (CLL) (10.6%) and Non-Hodgkin Lymphoma (NHL) (35.3%). Despite a high COVID-19 vaccination rate (97.6%), severe/critical illness occurred in 23.5% of patients. The overall COVID-19-related mortality rate was 22.4%, with a 30-day mortality rate of 11.8%. Although mortality rates significantly decreased over the observation time (27.7% vs. 16.7%), this trend was not confirmed in critical infection carriers.
CONCLUSION: Our data confirm that, despite a reduction in critical infections and overall mortality rates over time, patients with hematological malignancies remain at high risk during the endemic phase of SARS-CoV-2 infection.